Picture of Unity Biotechnology logo

UNBX — Unity Biotechnology News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Unity Biotechnology Inc Reports Results For The Quarter Ended In March: Earnings Summary

* UNITY Biotechnology Inc  UBX.OQ  reported a quarterly
adjusted
loss of 76 cents​​ per share for the quarter ended in March. The
mean expectation of four analysts for the quarter was for a loss
of $1.08 per share.
    * Reported revenue was zero​; analysts expected zero. 
    * UNITY Biotechnology Inc's reported EPS for the quarter was
a
loss of 76 cents​.
    * The mean earnings estimate of analysts had risen by
about 2.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * UNITY Biotechnology Inc shares had risen by 46.9% this
quarter and lost 12.6% so far this year.
    * The company reported a quarterly loss of $10.87 million.
    * Wall Street's median 12-month price target for UNITY
Biotechnology Inc is $10.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
9 at 11:59 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -1.08          -0.76          Beat
 Dec. 31 2022      -1.05          -1.00          Beat
 Sep. 30 2022      -1.65          -1.36          Beat
 Jun. 30 2022      -2.80          -1.90          Beat

Recent news on Unity Biotechnology

See all news